K-V gets FDA nod to reintroduce first drug; Allergan sues to block Latisse copy;

@FiercePharma: Nearly 400 Medicines and Vaccines in Development to Fight Infectious Diseases: PhRMA. Report | Follow @FiercePharma

> K-V Pharmaceutical has passed FDA inspection with its facilities and has won agency approval to put its first product back on the market, after manufacturing problems forced the company to stop production and enter into a consent decree with the agency. K-V release

> Allergan has filed a patent-infringement lawsuit in federal court in an attempt to stop Apotex from selling a generic version of the eyelash-enhancing drug Latisse before patent protection for the drug expires. Story

> Novo Nordisk is on track to receive NICE approval for its Type 2 diabetes drug Victoza, but will still have to settle on a lower dose. Item

> Britain's healthcare cost watchdog said it was unable to recommend use of Bristol-Myers Squibb's schizophrenia drug Abilify in children aged 15 to 17 and has asked for more information on its effectiveness. Report

> Daiichi Sankyo says its influenza treatment Inavir has been approved in Japan, becoming the second product in the new generation of influenza drugs to be commercialized in the country. Article

> A U.S. court has ruled that Danish drugmaker Lundbeck's acquisition of heart defect drug Neoprofen did not reduce market competition, giving the company's shares a boost. News

Biotech News

@FierceBiotech: Acceleron inks $498M pact with Shire for lead muscle drug. Article  Follow @FierceBiotech

 @JohnCFierce:New leak from BLMB: Genzyme investors demanding $75 from Sanofi. Absolutely, positively, lowest possible bid. Sure.  Article | Follow @JohnCFierce 

> Report: Approval success rates higher for smaller firms. Story

> Four drugs look to pass FDA muster this month. Item

> J&J unit's prostate cancer drug improves survival. Article

And Finally... Researchers identified a critical enzyme that keeps traffic flowing in the right direction in the nervous system, a finding that could eventually lead to new treatments for conditions such as Alzheimer's and Parkinson's disease. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.